nach oben

Current Osteoporosis Reports

Erschienen in:

01.03.2014 | Regenerative Biology and Medicine in Osteoporosis (EM Schwartz and RE Guldberg, Section Editors)

Stem Cell Therapy for Osteoporosis

verfasst von: Ben Antebi, Gadi Pelled, Dan Gazit

Erschienen in: Current Osteoporosis Reports | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Osteoporosis is a debilitating disease that affects millions of people worldwide. Current osteoporosis treatments are predominantly bone-resorbing drugs that are associated with several side effects. The use of stem cells for tissue regeneration has raised great hope in various fields of medicine, including musculoskeletal disorders. Stem cell therapy for osteoporosis could potentially reduce the susceptibility of fractures and augment lost mineral density by either increasing the numbers or restoring the function of resident stem cells that can proliferate and differentiate into bone-forming cells. Such osteoporosis therapies can be carried out by exogenous introduction of mesenchymal stem cells (MSCs), typically procured from bone marrow, adipose, and umbilical cord blood tissues or through treatments with drugs or small molecules that recruit endogenous stem cells to osteoporotic sites. The main hurdle with cell-based osteoporosis therapy is the uncertainty of stem cell fate and biodistribution following cell transplantation. Therefore, future advancements will focus on long-term engraftment and differentiation of stem cells at desired bone sites for tangible clinical outcome.

Cooper C, Campion G, Melton III LJ. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2:285–9.PubMedCrossRef

Foundation, NO. Debunking the Myths. 2013. Available at: http://www.nof.org/articles/4.

Lien CY et al. Restoration of bone mass and strength in glucocorticoid-treated mice by systemic transplantation of CXCR4 and cbfa-1 co-expressing mesenchymal stem cells. J Bone Miner Res. 2009;24:837–48.PubMedCrossRef

Martin KE et al. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost. J Manag Care Pharm. 2011;17:596–609.PubMed

Liu Y, et al. Therapeutic application of mesenchymal stem cells in bone and joint diseases. Clin Exp Med. 2012.

Sandhu SK, Hampson G. The pathogenesis, diagnosis, investigation and management of osteoporosis. J Clin Pathol. 2011;64:1042–50.PubMedCrossRef

Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194(2 Suppl):S3–S11.PubMedCrossRef

Lippuner K. The future of osteoporosis treatment - a research update. Swiss Med Wkly. 2012;142:w13624.PubMed

Chen XD et al. Extracellular matrix made by bone marrow cells facilitates expansion of marrow-derived mesenchymal progenitor cells and prevents their differentiation into osteoblasts. J Bone Miner Res. 2007;22:1943–56.PubMedCrossRef

10.

Chen XD et al. Age-related osteoporosis in biglycan-deficient mice is related to defects in bone marrow stromal cells. J Bone Miner Res. 2002;17:331–40.PubMedCrossRef

11.

Katsara O et al. Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 2011;20:1549–61.PubMedCrossRef

12.

Bonyadi M et al. Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null mice. Proc Natl Acad Sci U S A. 2003;100:5840–5.PubMedCentralPubMedCrossRef

13.

Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009;360:53–62.PubMedCentralPubMedCrossRef

14.

Khan AA et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2009;36:478–90.PubMedCrossRef

15.

Lo JC et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68:243–53.PubMedCrossRef

16.

Saleh A et al. Bisphosphonate therapy and atypical fractures. Orthop Clin North Am. 2013;44:137–51.PubMedCrossRef

17.

Nieves JW, Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep. 2010;8:34–9.PubMedCrossRef

18.

Cummings SR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.PubMedCrossRef

19.

Rizzoli R, Yasothan U, Kirkpatrick P. Denosumab. Nat Rev Drug Discov. 2010;9:591–2.PubMedCrossRef

20.

Barrett-Connor E et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–37.PubMedCrossRef

21.

Reginster JY, Pelousse F, Bruyere O. Safety concerns with the long-term management of osteoporosis. Expert Opin Drug Saf. 2013;12:507–22.PubMedCrossRef

22.

Anastasilakis AD et al. Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag. 2012;8:295–306.PubMedCentralPubMedCrossRef

23.

Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357:905–16.PubMedCrossRef

24.

Black DM et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353:555–65.PubMedCrossRef

25.••

Yao W, et al. Reversing bone loss by directing mesenchymal stem cells to the bone. Stem Cells. 2013. Important article describing a novel, small molecule to direct MSCs to bone to augment the rate of bone formation for osteoporosis treatment.

26.•

Steinert AF et al. Concise review: the clinical application of mesenchymal stem cells for musculoskeletal regeneration: current status and perspectives. Stem Cells Transl Med. 2012;1:237–47. A concise, yet detailed review on clinical applications of MSCs in the musculoskeletal system..PubMedCentralPubMedCrossRef

27.

Trounson A et al. Clinical trials for stem cell therapies. BMC Med. 2011;9:52.PubMedCentralPubMedCrossRef

28.

Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev. 2006;5:91–116.PubMedCrossRef

29.

Brack AS, Rando TA. Intrinsic changes and extrinsic influences of myogenic stem cell function during aging. Stem Cell Rev. 2007;3:226–37.PubMedCrossRef

30.

Muschler GF et al. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res. 2001;19:117–25.PubMedCrossRef

31.

Wang Z et al. Efficacy of bone marrow-derived stem cells in strengthening osteoporotic bone in a rabbit model. Tissue Eng. 2006;12:1753–61.PubMedCrossRef

32.

Ocarino Nde M et al. Intra-bone marrow injection of mesenchymal stem cells improves the femur bone mass of osteoporotic female rats. Connect Tissue Res. 2010;51:426–33.PubMedCrossRef

33.

Tang Y et al. Combination of bone tissue engineering and BMP-2 gene transfection promotes bone healing in osteoporotic rats. Cell Biol Int. 2008;32:1150–7.PubMedCrossRef

34.

Hsiao FS et al. Isolation of therapeutically functional mouse bone marrow mesenchymal stem cells within 3 h by an effective single-step plastic-adherent method. Cell Prolif. 2010;43:235–48.PubMedCrossRef

35.

Kim D et al. Retrovirus-mediated gene transfer of receptor activator of nuclear factor-kappaB-Fc prevents bone loss in ovariectomized mice. Stem Cells. 2006;24:1798–805.PubMedCrossRef

36.

Cho SW et al. Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice. Mol Ther. 2009;17:1979–87.PubMedCrossRef

37.•

Levi B, Longaker MT. Concise review: adipose-derived stromal cells for skeletal regenerative medicine. Stem Cells. 2011;29:576–82. This article highlights the emerging role of adipose derived stem cells in skeletal tissue engineering..PubMedCentralPubMedCrossRef

38.

Liu HY et al. The effect of diminished osteogenic signals on reduced osteoporosis recovery in aged mice and the potential therapeutic use of adipose-derived stem cells. Biomaterials. 2012;33:6105–12.PubMedCrossRef

39.

Chen HT et al. Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. J Cell Mol Med. 2012;16:582–93.PubMedCrossRef

40.

Cho SW et al. Human adipose tissue-derived stromal cell therapy prevents bone loss in ovariectomized nude mouse. Tissue Eng Part A. 2012;18:1067–78.PubMedCrossRef

41.

Rodriguez JP et al. Abnormal osteogenesis in osteoporotic patients is reflected by altered mesenchymal stem cells dynamics. J Cell Biochem. 1999;75:414–23.PubMedCrossRef

42.

Rodriguez JP et al. Involvement of adipogenic potential of human bone marrow mesenchymal stem cells (MSCs) in osteoporosis. Curr Stem Cell Res Ther. 2008;3:208–18.PubMedCrossRef

43.

You L et al. Suppression of zinc finger protein 467 alleviates osteoporosis through promoting differentiation of adipose derived stem cells to osteoblasts. J Transl Med. 2012;10:11.PubMedCentralPubMedCrossRef

44.•

Ilic D, Miere C, Lazic E. Umbilical cord blood stem cells: clinical trials in non-hematological disorders. Br Med Bull. 2012;102:43–57. This article provides detailed information regarding umbilical cord blood MSCs and their use in relevant clinical trials..PubMedCrossRef

45.

Rebelatto CK et al. Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med. 2008;233:901–13.CrossRef

46.

Guillot PV et al. Comparative osteogenic transcription profiling of various fetal and adult mesenchymal stem cell sources. Differentiation. 2008;76:946–57.PubMed

47.

An JH et al. Transplantation of human umbilical cord blood-derived mesenchymal stem cells or their conditioned medium prevents bone loss in ovariectomized nude mice. Tissue Eng Part A. 2013;19:685–96.PubMedCrossRef

48.

Aggarwal R et al. Human umbilical cord blood-derived CD34+ cells reverse osteoporosis in NOD/SCID mice by altering osteoblastic and osteoclastic activities. PLoS One. 2012;7:e39365.PubMedCentralPubMedCrossRef

49.

Nishida S et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone. 1994;15:717–23.PubMedCrossRef

50.

Davies J, Chambers TJ. Parathyroid hormone activates adhesion in bone marrow stromal precursor cells. J Endocrinol. 2004;180:505–13.PubMedCrossRef

51.

Mukherjee S et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest. 2008;118:491–504.PubMedCentralPubMed

52.••

Guan M et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med. 2012;18:456–62. Important article describing a novel, small molecule to direct MSCs to bone to augment the rate of bone formation for osteoporosis treatment..PubMedCentralPubMedCrossRef

53.

Lopez FJ. New approaches to the treatment of osteoporosis. Curr Opin Chem Biol. 2000;4:383–93.PubMedCrossRef

54.

Petersson M et al. Oxytocin stimulates proliferation of human osteoblast-like cells. Peptides. 2002;23:1121–6.PubMedCrossRef

55.

Elabd SK et al. Possible neuroendocrine role for oxytocin in bone remodeling. Endocr Regul. 2007;41:131–41.PubMed

56.

Elabd C et al. Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis. Stem Cells. 2008;26:2399–407.PubMedCrossRef

57.

Meyerrose TE et al. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells. 2007;25:220–7.PubMedCrossRef

58.

Granero-Molto F et al. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells. 2009;27:1887–98.PubMedCentralPubMedCrossRef

59.

Gutwald R et al. Mesenchymal stem cells and inorganic bovine bone mineral in sinus augmentation: comparison with augmentation by autologous bone in adult sheep. Br J Oral Maxillofac Surg. 2010;48:285–90.PubMedCrossRef

60.

Vertenten G et al. Evaluation of an injectable, photopolymerizable, and three-dimensional scaffold based on methacrylate-endcapped poly(D, L-lactide-co-epsilon-caprolactone) combined with autologous mesenchymal stem cells in a goat tibial unicortical defect model. Tissue Eng Part A. 2009;15:1501–11.PubMedCrossRef

61.

Halleux C et al. Multi-lineage potential of human mesenchymal stem cells following clonal expansion. J Musculoskelet Neuronal Interact. 2001;2:71–6.PubMed

62.

Longobardi L et al. Subcellular localization of IRS-1 in IGF-I-mediated chondrogenic proliferation, differentiation and hypertrophy of bone marrow mesenchymal stem cells. Growth Factors. 2009;27:309–20.PubMedCrossRef

63.

Ma L et al. Cryopreserved dental pulp tissues of exfoliated deciduous teeth is a feasible stem cell resource for regenerative medicine. PLoS One. 2012;7:e51777.PubMedCentralPubMedCrossRef

64.

Vishwanath VR et al. Differentiation of isolated and characterized human dental pulp stem cells and stem cells from human exfoliated deciduous teeth: An in vitro study. J Conserv Dent. 2013;16:423–8.PubMedCentralPubMedCrossRef

65.

Alkaisi A et al. Transplantation of human dental pulp stem cells: enhance bone consolidation in mandibular distraction osteogenesis. J Oral Maxillofac Surg. 2013;71:1758. e1–13.PubMedCrossRef

Titel: Stem Cell Therapy for Osteoporosis
verfasst von: Ben Antebi
Gadi Pelled
Dan Gazit
Publikationsdatum: 01.03.2014
Verlag: Springer US
Erschienen in: Current Osteoporosis Reports / Ausgabe 1/2014
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-013-0184-x

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Biomaterial Scaffolds for Treating Osteoporotic Bone

Local Strategies to Prevent and Treat Osteoporosis

Bone and the Innate Immune System

Apoptotic Osteocytes and the Control of Targeted Bone Resorption

Impact of Inflammation on the Osteoblast in Rheumatic Diseases